Zhang Ming-Man, Li De-Hua, Yan Lü-Ian, Gou Xing-Hua, Zhao Yong-Heng, Su Zhi, Huang Ying-Chun, Han Lei, Zhao Lan-Ying, Hu Hai-Yang
Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Nov;36(6):765-9.
To construct a recombinant adeno-associated virus vectors carrying double gene of antisense multidrug resistance-associated protein (MRP) and antisense multidrug resistance (MDR1) for use in studying the gene therapy to reverse the multidrug resistance (MDR) in hepatocellular carcinoma (HCC).
The 500 bp fragment (mrp) of MRP cDNA 5' region and the 600 bp fragment (mdr1) of MDR1 cDNA 5' region were amplified through polymerase chain reaction (PCR), and then they were linked to a combined gene fragment (mrp+mdrl) by overlapping technique. The combined gene fragment(mrp+mdrl) was cloned reversely into the multiple cloning site (MCS) of the expression plasmid pAAV-IRES-hrGFP in AAV Helper-Free System to construct the recombinant expression plasmid pAAV-IRES-hrGFP-(mrp + mdr1)AS. The packaging cell line (HEK 293 cell) was co-transfected with the pAAV-IRES-hrGFP-(mrp+mdr1)AS together with the control plasmid pAAV-RC and pHelper in AAV Helper-Free System by means of lipofectamine. The recombinant adeno-associated virus vector : rAAV2-(mrp+mdr1)AS carrying the double gene of antisense multidrug resistance-associated protein (MRP)and antisense multidrug resistance (MDR1) was packaged. Then the viral titer was checked by GFP.
The recombinant adeno-associated virus vector : rAAV2-(mrp + mdr1)AS carrying antisense MRP and antisense MDR1 was constructed successfully, the strong green fluorescence was observed in HEK 293 cells under a fluorescence microscope. The viral titer was 2.5 X 10(6) efu/ml.
The rAAV2-(mrp+mdr1)AS thus constructed could introduce the antisense MRP and antisense MDR1 into the human drug-resistant hepatocellular cell line effectively, which might provide a sound basis for the mechanisms and reversal methods of the multidrug resistance in HCC.
构建携带反义多药耐药相关蛋白(MRP)和反义多药耐药(MDR1)双基因的重组腺相关病毒载体,用于研究逆转肝细胞癌(HCC)多药耐药(MDR)的基因治疗。
通过聚合酶链反应(PCR)扩增MRP cDNA 5'区域的500 bp片段(mrp)和MDR1 cDNA 5'区域的600 bp片段(mdr1),然后通过重叠技术将它们连接成一个联合基因片段(mrp+mdrl)。将联合基因片段(mrp+mdrl)反向克隆到无辅助腺相关病毒系统中表达质粒pAAV-IRES-hrGFP的多克隆位点(MCS),构建重组表达质粒pAAV-IRES-hrGFP-(mrp + mdr1)AS。采用脂质体转染法,将pAAV-IRES-hrGFP-(mrp+mdr1)AS与对照质粒pAAV-RC和pHelper在无辅助腺相关病毒系统中共同转染包装细胞系(HEK 293细胞)。包装携带反义多药耐药相关蛋白(MRP)和反义多药耐药(MDR1)双基因重组腺相关病毒载体:rAAV2-(mrp+mdr1)AS。然后通过绿色荧光蛋白(GFP)检测病毒滴度。
成功构建携带反义MRP和反义MDR1的重组腺相关病毒载体:rAAV2-(mrp + mdr1)AS,荧光显微镜下可见HEK 293细胞发出强烈绿色荧光。病毒滴度为2.5×10(6) efu/ml。
构建的rAAV2-(mrp+mdr1)AS能有效将反义MRP和反义MDR1导入人耐药肝癌细胞系,可能为HCC多药耐药机制及逆转方法研究提供良好基础。